
A key mechanistic point is a novel interaction between RAD18 and the tumor suppressor NF2/Merlin through the RAD18 SAP domain, with consequences for inhibition of the Hippo/YAP pathway.

A key mechanistic point is a novel interaction between RAD18 and the tumor suppressor NF2/Merlin through the RAD18 SAP domain, with consequences for inhibition of the Hippo/YAP pathway.